Metoclopramide Accord (Metoclopramide Hydrochloride)

Metoclopramide is employed in the management of several gastrointestinal and peri‑operative conditions where nausea, vomiting or delayed gastric emptying are present.

• Nausea and vomiting: reduces the frequency and severity of episodes in adults.
• Gastroparesis: improves gastric motility and accelerates stomach emptying.
• Gastro‑oesophageal reflux disease (GERD): alleviates reflux‑related symptoms by enhancing lower esophageal sphincter tone.
• Pre‑operative and post‑operative nausea: prevents or treats nausea associated with anesthesia and surgery.

• Metoclopramide exerts its effect by antagonizing peripheral and central dopamine D2 receptors, which diminishes the chemoreceptor trigger zone stimulation and promotes gastrointestinal motility. In addition, it blocks serotonin 5‑HT3 receptors and stimulates 5‑HT4 receptors, further enhancing acetylcholine release in the gut and accelerating gastric emptying. These combined actions increase the tone of the upper gastrointestinal tract, facilitate coordinated peristalsis, and reduce the sensation of nausea.

Metoclopramide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Drowsiness: feeling of sleepiness or reduced alertness that may affect daily activities.
• Restlessness: inner sense of agitation or inability to stay still.
• Diarrhea: loose, frequent stools that can lead to dehydration.
• Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects

• Tardive dyskinesia: involuntary, repetitive movements that may become irreversible.
• Neuroleptic malignant syndrome: high fever, muscle rigidity, and autonomic instability.
• Severe depression or suicidal thoughts: marked mood changes requiring immediate medical attention.
• Allergic reactions: rash, itching, swelling, or anaphylaxis that demand prompt treatment.

When prescribing Metoclopramide Accord, clinicians should observe several safety measures.

• Neurological assessment: evaluate patients for extrapyramidal symptoms before and during therapy.
• Dose limitation: use the lowest effective dose and limit treatment duration, generally not exceeding 12 weeks.
• Contraindications: avoid use in patients with pheochromocytoma or known hypersensitivity to metoclopramide.
• Pregnancy and lactation: consider risk‑benefit; drug is category B but use only if clearly needed.
• Monitoring: observe for signs of depression, tardive dyskinesia, or cardiac arrhythmia during prolonged use.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoclopramide can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis or serotonin syndrome.
• Anticholinergic agents: can reduce the pro‑kinetic efficacy of metoclopramide.
• CNS depressants (e.g., opioids, benzodiazepines): increase risk of sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., codeine, tramadol): metoclopramide may inhibit metabolism, raising plasma levels.
• Antipsychotics (e.g., haloperidol): additive dopamine antagonism may enhance extrapyramidal effects.